The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Celgene
Leadership - Celgene
Stock and Other Ownership Interests - Celgene
Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
 
Volker Kunzmann
Consulting or Advisory Role - Celgene
 
Ramesh K. Ramanathan
Honoraria - See under advisory Boards
Consulting or Advisory Role - Caris Life Sciences; Celgene; Genentech; Immunomedics; Lilly; Sanofi; Sanofi; Taiho Pharmaceutical; Vaccinex
Speakers' Bureau - Celgene
Research Funding - Abbvie; AVEO; Bayer; Biomarin; Celgene; Dekkun Corporation; Endocyte; Genentech; Halozyme; Merck/Schering Plough; Merrimack; Sanofi; Tekmira; Vaccinex; Verastem
Travel, Accommodations, Expenses - Biomarin
 
David Goldstein
Consulting or Advisory Role - Celgene
Research Funding - Celgene
 
Darryl Neil Penenberg
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Stefano Ferrara
Employment - Celgene
Leadership - Celgene
Stock and Other Ownership Interests - Celgene
 
Brian Lu
No Relationships to Disclose
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Cell Therapeutics; Insys Therapeutics; McKesson; Medtronic
Honoraria - Celgene; Cerulean Pharma; Clarion Healthcare; Daiichi Sankyo; Genentech; Immunomedics; International Genomics Consortium; McKesson; Novartis; OncoMed; Peregrine Pharmaceuticals; Precision Medicine Research Associates, LLC; Puma Biotechnology
Consulting or Advisory Role - 3-V Biosciences; AgencyRx; Agenus; Aileron Therapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Arsia Therapeutics; Arvinas; Azaya Therapeutics; Bellicum Pharmaceuticals; Biological Dynamics; Biomarin; Bionomics; Bristol-Myers Squibb; Buhl Oncology; CanBas; Caris Life Sciences; Cavion; Cerulean Pharma; CTI; CytRx Corporation; Daiichi Sankyo; dalian wanchun biotechnology; DNAtrix; Esperance Pharmaceuticals; Five Prime Therapeutics; Formula Pharmaceuticals; Halozyme; HealthCare Pharmaceuticals; Horizon Discovery; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunomedics; Inform Genomics; Innate Pharma; Insys Therapeutics; Invivodata; Kinex; Lilly; Lixte Biotechnology; Lorus; MBC Pharma; Medelis; MediaPharma; Medical Prognosis Institute; Merus; miRNA Therapeutics; Momenta Pharmaceuticals; Nereus Pharmaceuticals; Novartis; Nucana; Oncology Venture; Oncolytics; Oncolyze; OncoMed; Pain Therapeutics; Peregrine Pharmaceuticals; Pharmacyclics; Pharmatech; Pledpharma; Precision Medicine Research Associates, LLC; Puma Biotechnology; RadioRx; Reflexion Medical; RenovoRx; Samsung; Samumed; Senhwa Biosciences; Superlab Far East; SynDevRx; TD2; Teva; Theravance; TNI Biotech; Tolero Pharmaceuticals; Toray Industries; Trovagene; Vaccinex; VidaCare
Research Funding - 3-V Biosciences (Inst); Abraxis BioScience (Inst); Agios (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Plexxikon (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - Aileron Therapeutics; Bionomics; Caris Life Sciences; Celgene; Cell Therapeutics; Cerulean Pharma; Cylene; Daiichi Sankyo; DNAtrix; Five Prime Therapeutics; FORMA Therapeutics; Halozyme; Innate Pharma; Lilly; McKesson; Medical Prognosis Institute; miRNA Therapeutics; Novartis; Oncolytics; Partners Healthcare; Quintiles; RadioRx; Senhwa Biosciences; Vaccinex